NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	14.77 $	+16.39%	2,785,740
26-01-15	12.69 $	-0.31%	1,019,685
26-01-14	12.73 $	-2.38%	906,255
26-01-13	13.04 $	-3.05%	1,418,419
26-01-12	13.45 $	-29.80%	3,008,309

Delayed Quote Nyse, January 16, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nyse Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
14.77 ^USD	+16.39%		-22.91%	+161.88%

Dec. 19	Wall Street Set to Open Little Changed as Investors Await Home Sales, Consumer Sentiment Data	MT
Nov. 07	NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Capitalization	711M 610M 566M 529M 985M 64.58B 1.06B 6.54B 2.58B 30.75B 2.67B 2.61B 112B	P/E ratio 2023	-0.05x	P/E ratio 2024	-0.24x
Enterprise value	712M 611M 567M 530M 987M 64.69B 1.06B 6.56B 2.58B 30.8B 2.67B 2.62B 113B	EV / Sales 2023	0.06x	EV / Sales 2024	0.43x
Free-Float	99.99%	Yield 2023 *	-	Yield 2024	-

Dec. 19	Wall Street Set to Open Little Changed as Investors Await Home Sales, Consumer Sentiment Data	MT
Nov. 07	NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-09	Novabay Pharmaceuticals says David Lazar resigns as CEO	RE
25-10-09	NovaBay Pharmaceuticals, Inc. Announces Resignation of David Lazar as Director	CI
25-10-09	NovaBay Pharmaceuticals, Inc. Announces Resignation of David Lazar as CEO	CI
25-10-03	Novabay Pharmaceuticals files for mixed shelf of up to $200 million - SEC filing	RE
25-08-27	Top Midday Gainers	MT
25-08-26	NovaBay Pharmaceuticals Declares Special Cash Dividend of $0.80 a Share, Payable Sept. 29 to Holders of Record Sept. 15	MT
25-08-26	Novabay Pharmaceuticals announces one-time special cash dividend of $0.80 per share	RE
25-08-25	NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025	CI
25-08-19	NovaBay Pharmaceuticals enters into $6 million securities purchase agreement with investor David Lazar	RE
25-08-19	Novabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025	CI
25-08-19	Novabay Pharmaceuticals, Inc. Appoints Tommy Law as Chief Financial Officer, Effective August 19, 2025	CI

25-10-09	NovaBay Pharmaceuticals, Inc. Announces Resignation of David Lazar as CEO	CI
23-08-11	Ladenburg Thalmann Cuts Price Target on NovaBay Pharmaceuticals to $3.80 From $6, Maintains Buy Rating	MT
21-10-07	NOVABAY PHARMACEUTICALS : Ladenburg Thalmann Adjusts NovaBay Pharmaceuticals PT to $2.20 From $1.90, Maintains Buy Rating	MT

NovaBay Pharmaceuticals, Inc. Stock

Equities

NBY

US66987P4090

Pharmaceuticals

Valuation: NovaBay Pharmaceuticals, Inc.

Chart: NovaBay Pharmaceuticals, Inc.

Latest news: NovaBay Pharmaceuticals, Inc.

Analysts' recommendations: NovaBay Pharmaceuticals, Inc.

Press Releases: NovaBay Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NovaBay Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

25-10-22	NovaBay Pharmaceuticals : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)	PU
25-10-20	NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards	GL
25-09-18	NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting	GL
25-08-21	Investor Alert: NBY, OP, STAI, PNPNF - Stocks Under $1 Complete Watch List Inside	AQ
25-08-19	NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar	GL

1 day	+16.39%
1 week	-22.91%
Current month	+161.88%
1 month	+400.68%
3 months	+1,320.19%
6 months	+2,127.75%
Current year	+161.88%

1 week	10.42	18.4
1 month	4.31	19.95
Current year	5.47	19.95
1 year	0.46	19.95
3 years	0.36	91.7
5 years	0.36	2,192.75
10 years	0.36	6,480.26

Manager	Title	Age	Since
Tommy Law DFI	Director of Finance/CFO	40	2023-02-14
Justin Hall CEO	Chief Executive Officer	49	2019-03-07

Director	Title	Age	Since
Paul Freiman CHM	Chairman	92	2019-03-11
Yen You Zheng BRD	Director/Board Member	69	2019-09-10
Swan Sit BRD	Director/Board Member	49	2019-12-16

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NOVABAY PHARMACEUTICALS, INC.	+16.39%	-22.91%	+1,916.11%	-81.24%	1.86B
ELI LILLY AND COMPANY	+0.53%	-2.37%	+43.09%	+194.99%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+48.72%	+28.81%	527B
ABBVIE INC.	-1.11%	-2.60%	+24.94%	+43.67%	379B
ROCHE HOLDING AG	-0.60%	+1.26%	+29.94%	+17.78%	371B
ASTRAZENECA PLC	-1.15%	-1.63%	+28.68%	+21.63%	292B
NOVARTIS AG	-0.03%	+1.51%	+29.51%	+36.74%	276B
MERCK & CO., INC.	-1.93%	-1.54%	+11.14%	+0.04%	270B
NOVO NORDISK A/S	-2.92%	-0.41%	-31.52%	-21.19%	268B
AMGEN INC.	+0.12%	+1.32%	+21.43%	+24.97%	178B
Average	+0.85%	-1.66%	+212.20%	+26.62%	349.28B
Weighted average by Cap.	-0.60%	+0.49%	+29.99%	+67.19%

	2023	2024
Net sales	14.73M 12.65M 11.74M 10.96M 20.41M 1.34B 21.94M 136M 53.4M 637M 55.23M 54.09M 2.33B	9.78M 8.4M 7.79M 7.28M 13.56M 889M 14.57M 90.06M 35.47M 423M 36.68M 35.93M 1.55B
Net income	-9.64M -8.28M -7.68M -7.18M -13.36M -876M -14.36M -88.76M -34.96M -417M -36.15M -35.41M -1.52B	-7.22M -6.2M -5.76M -5.38M -10.01M -656M -10.76M -66.51M -26.19M -312M -27.09M -26.53M -1.14B
Net Debt	-390K -335K -311K -290K -541K -35.44M -581K -3.59M -1.41M -16.87M -1.46M -1.43M -61.66M	1.24M 1.07M 990K 925K 1.72M 113M 1.85M 11.44M 4.5M 53.73M 4.66M 4.56M 196M